Patents by Inventor Minyong Chen
Minyong Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11390862Abstract: Provided herein is a thermolabile proteinase and methods of using the same. In some embodiments, the thermolabile proteinase may comprise an amino acid sequence that is at least 90% identical to any of SEQ ID NOs:1-11 and at least one amino acid substitution in helix 3. The thermolabile proteinase is active at a temperature in the range of 4° C.-40° C. and is inactivated by raising the temperature to above 50° C., where the proteinase is substantially inactive at 65° C.Type: GrantFiled: December 21, 2020Date of Patent: July 19, 2022Assignee: New England Biolabs, Inc.Inventors: Minyong Chen, James C. Samuelson, Ming-Qun Xu, Aihua Zhang, Margaret Heider, Pingfang Liu
-
Publication number: 20210115427Abstract: Provided herein is a thermolabile proteinase and methods of using the same. In some embodiments, the thermolabile proteinase may comprise an amino acid sequence that is at least 90% identical to any of SEQ ID NOs:1-11 and at least one amino acid substitution in helix 3. The thermolabile proteinase is active at a temperature in the range of 4° C.-40° C. and is inactivated by raising the temperature to above 50° C., where the proteinase is substantially inactive at 65° C.Type: ApplicationFiled: December 21, 2020Publication date: April 22, 2021Applicant: New England Biolabs, Inc.Inventors: Minyong Chen, James C. Samuelson, Ming-Qun Xu, Aihua Zhang, Margaret Heider, Pingfang Liu
-
Patent number: 10905665Abstract: Described are methods of treating a disease associated with dysregulation of the Wnt/Frizzled signaling pathway. The methods include identifying subjects in need of therapy, administering inhibitors of the Wnt/Frizzled signaling pathway, pharmaceutical compositions including the inhibitors, and methods of using the compounds and compositions for treating cancer, bacterial and viral infection, lupus, type II diabetes, nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD) in a subject.Type: GrantFiled: June 24, 2016Date of Patent: February 2, 2021Assignee: Duke UniversityInventors: Wei Chen, Robert A. Mook, Jr., Jiangbo Wang, Xiu-rong Ren, Minyong Chen, Lawrence S. Barak, Herbert Kim Lyerly, David Needham
-
Publication number: 20200199565Abstract: Provided herein is a thermolabile proteinase and methods of using the same. In some embodiments, the thermolabile proteinase may comprise an amino acid sequence that is at least 90% identical to any of SEQ ID NOs:1-11 and at least one amino acid substitution in helix 3. The thermolabile proteinase is active at a temperature in the range of 4° C.-40° C. and is inactivated by raising the temperature to above 50° C., where the proteinase is substantially inactive at 65° C.Type: ApplicationFiled: December 18, 2019Publication date: June 25, 2020Applicant: New England Biolabs, Inc.Inventors: Minyong Chen, James C. Samuelson, Ming-Qun Xu, Aihua Zhang, Margaret Heider, Pingfang Liu
-
Patent number: 10633644Abstract: Provided herein is a thermolabile proteinase and methods of using the same. In some embodiments, the thermolabile proteinase may comprise an amino acid sequence that is at least 90% identical to any of SEQ ID NOs:1-11 and at least one amino acid substitution in helix 3. The thermolabile proteinase is active at a temperature in the range of 4° C.-40° C. and is inactivated by raising the temperature to above 50° C., where the proteinase is substantially inactive at 65° C.Type: GrantFiled: December 18, 2019Date of Patent: April 28, 2020Assignee: New England Biolabs, Inc.Inventors: Minyong Chen, James C. Samuelson, Ming-Qun Xu, Aihua Zhang, Margaret Heider, Pingfang Liu
-
Publication number: 20200038350Abstract: Described are methods of treating a disease associated with dysregulation of the Wnt/Frizzled signaling pathway. The methods include identifying subjects in need of therapy, administering inhibitors of the Wnt/Frizzled signaling pathway, pharmaceutical compositions including the inhibitors, and methods of using the compounds and compositions for treating cancer, bacterial and viral infection, lupus, type II diabetes, nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD) in a subject.Type: ApplicationFiled: June 24, 2016Publication date: February 6, 2020Inventors: Wei Chen, Robert A. Mook, JR., Jiangbo Wang, Xiu-rong Ren, Minyong Chen, Lawrence S. Barak, Herbert Kim Lyerly, David Needham
-
Patent number: 10507233Abstract: Methods of capturing N-glycan linked glycomolecules including N-glycans, N-glycopeptides and N-glycoproteins are described. The methods provide substantially unbiased capture of charged and uncharged N-glycans and/or N-glycan linked glycomoleules. Binding reagents for substantially unbiased binding of N-glycans and/or N-glycan linked glycomolecules are also described.Type: GrantFiled: August 20, 2018Date of Patent: December 17, 2019Assignee: New England Biolabs, Inc.Inventors: Minyong Chen, Xiaofeng Shi, James C. Samuelson, Christopher H. Taron
-
Publication number: 20190070154Abstract: Described are methods of treating a disease associated with dysregulation of the Wnt/Frizzled signaling pathway. The methods include identifying subjects in need of therapy, administering inhibitors of the Wnt/Frizzled signaling pathway, pharmaceutical compositions including the inhibitors, and methods of using the compounds and compositions for treating cancer, bacterial Sand viral infection, lupus, type II diabetes, nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD) in a subject.Type: ApplicationFiled: June 24, 2016Publication date: March 7, 2019Inventors: Wei Chen, Robert A. Mook, Jr., Jiangbo Wang, Xiu-rong Ren, Minyong Chen, Lawrence S. Barak, Herbert Kim Lyerly
-
Publication number: 20190008934Abstract: Methods of capturing N-glycan linked glycomolecules including N-glycans, N-glycopeptides and N-glycoproteins are described. The methods provide substantially unbiased capture of charged and uncharged N-glycans and/or N-glycan linked glycomoleules. Binding reagents for substantially unbiased binding of N-glycans and/or N-glycan linked glycomolecules are also described.Type: ApplicationFiled: August 20, 2018Publication date: January 10, 2019Applicant: New England Biolabs, Inc.Inventors: Minyong Chen, Xiaofeng Shi, James C. Samuelson, Christopher H. Taron
-
Patent number: 10080787Abstract: Methods of capturing N-glycan linked glycomolecules including N-glycans, N-glycopeptides and N-glycoproteins are described. The methods provide substantially unbiased capture of charged and uncharged N-glycans and/or N-glycan linked glycomolecules. Binding reagents for substantially unbiased binding of N-glycans and/or N-glycan linked glycomolecules are also described.Type: GrantFiled: June 26, 2015Date of Patent: September 25, 2018Assignee: New England Biolabs, Inc.Inventors: Minyong Chen, Xiaofeng Shi, James C. Samuelson, Christopher H. Taron
-
Publication number: 20170128554Abstract: Methods of capturing N-glycan linked glycomolecules including N-glycans, N-glycopeptides and N-glycoproteins are described. The methods provide substantially unbiased capture of charged and uncharged N-glycans and/or N-glycan linked glycomolecules. Binding reagents for substantially unbiased binding of N-glycans and/or N-glycan linked glycomolecules are also described.Type: ApplicationFiled: June 26, 2015Publication date: May 11, 2017Applicant: New England Biolabs, Inc.Inventors: Minyong Chen, Xiaofeng Shi, James C. Samuelson, Christopher H. Taron
-
Publication number: 20130005802Abstract: Methods of treating Wnt/Frizzled-related diseases, comprising administering niclosamide compounds are provided. Methods of predicting whether a disease will respond to treatment with a niclosamide compound are also provided.Type: ApplicationFiled: September 21, 2010Publication date: January 3, 2013Inventors: Wei Chen, Minyong Chen, H. Kim Lyerly, Lawrence S. Barak, Robert Mook, Takuya Osada, Michael A. Morse
